Axim Planning & Wealth’s Cellebrite CLBT Stock Holding History

Axim Planning & Wealth’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,800	Closed	-$173K	–	89
2025 Q2	$173K	Buy	+10,800	New	+$193K	0.16%	67

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

Axim Planning & Wealth's CLBT Position: Q3 2025 in Review

Axim Planning & Wealth sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 10,800 shares — an estimated $173K sold.

Axim Planning & Wealth first reported a position in CLBT in Q2 2025 and held it in 1 quarter. The position peaked at $173K in Q2 2025. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

Axim Planning & Wealth reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
Axim Planning & Wealth sold 10,800 Cellebrite shares in Q3 2025, an estimated $173K.
Axim Planning & Wealth first reported a position in Cellebrite in Q2 2025 and held it in 1 quarter.
Axim Planning & Wealth's Cellebrite position peaked at $173K in Q2 2025.
197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on Axim Planning & Wealth's 13F filing for Q3 2025, filed 5 Nov 2025.